Nurix Therapeutics GAAP EPS of $4.73 beats by $1.64, revenue of $673.1M beats by $193.58M (NASDAQ:NRIX)

Nurix Therapeutics (NRIX) reported Q3 GAAP EPS of $4.73, exceeding estimates by $1.64. Revenue reached $673.1M, up 8420.3% year-over-year and $193.58M above expectations. Cash reserves grew to $1.1B by August 31, 2026, from $592.9M in November 2025, according to the company.

Original reporting
Published Oct 12, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NRIX
Bullish
high confidence
Mentioned
$NRIX
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$NRIXBullishMed
01

Why it matters

The earnings surprise is likely to trigger short‑term buying pressure, though long‑term performance depends on pipeline execution.

02

Market read

First‑report earnings beat for NRIX provides fresh actionable information for traders.

03

What to watch

Sustaining such growth may require continued pipeline success; any upcoming trial setbacks could reverse gains.

Relevance 7/10Novelty 8/10Timing: today

Background

Nurix Therapeutics released its Q3 2026 earnings, highlighting a substantial revenue surge and cash accumulation.

Company-level read

Ticker impact

$NRIXBullishHigh confidence
Context

Q3 GAAP EPS $4.73 beats expectations by $1.64 and revenue $673.1M beats by $193.58M.

Expected impact

upward pressure as the market prices in the earnings beat

Evidence & confidence

Both EPS and revenue significantly exceeded forecasts, and cash balances more than doubled, indicating improved financial health.

Market effects

Biotech sector may see modest uplift as a peer demonstrates strong earnings momentum.

US biotech investors could re‑allocate capital toward NRIX and similar small‑cap innovators.

Limited to investors tracking US‑listed biotech earnings.

Counterpoint

The beat may be priced in quickly, and high valuation could limit upside.

Key entities

  • Nurix Therapeutics

    US‑listed biotech firm (NASDAQ:NRIX) reporting Q3 results.

Related articles

Med

Nurix Therapeutics stock is up, what you need to know

Nurix Therapeutics (NRIX) shares rose 3.4% after appointing Dr. Arati V. Rao as chief medical officer. Dr. Rao will oversee clinical development, including the BTK degrader bexobrutideg partnered with Roche. The stock closed at $16.33, up 2.8% from the previous close. Nurix has faced volatility, including a 39.8% drop last week due to Sanofi ending a Phase 1 study. The company has $1.1B in cash, funding operations into 2029.

$NRIXHighAI 8/10

StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate

Nurix Therapeutics (NRIX) shares fell 38% after Sanofi (SNY) terminated development of a key Phase I immunology candidate, SAR448272 (NX-3911), under their collaboration. Despite this, the rest of the collaboration remains intact, and Nurix maintains a strong cash position. Analysts note Nurix's potential in the oral protein degrader space, particularly its partnership with Roche (RO) for bexobrutideg (NX-5948), which targets a $48B market opportunity across five diseases.

$NRIXMedAI 8/10

Nurix to present bexobrutideg data at ASH meeting

Nurix Therapeutics (NASDAQ:NRIX) will present Phase 1a/1b study data for bexobrutideg at the ASH meeting in December 2026. The data shows clinical activity and tolerability at 600 mg daily. The drug is being developed with Roche for treating relapsed/refractory CLL and SLL. Nurix is also conducting multiple clinical trials, including Phase 2 and 3 studies.